Base de dados : MEDLINE
Pesquisa : D04.210.500.054.040.632 [Categoria DeCS]
Referências encontradas : 374 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 38 ir para página                         

  1 / 374 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27639703
[Au] Autor:Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
[Ad] Endereço:Division of Hematology/Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon, 14584, South Korea.
[Ti] Título:Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
[So] Source:Leuk Res;50:21-28, 2016 Nov.
[Is] ISSN:1873-5835
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Angiogenesis occurs in response to tissue ischemia and wound healing, and contributes to the pathogenesis of a variety of diseases, such as benign and malignant neoplasia. Several studies have measured bone marrow microvessel density (MVD) in MDS patients and acute myeloid leukemia (AML) patients transformed from MDS, and MVD was higher in MDS patients than controls, but was lower than in AML patients. Vascular endothelial growth factor (VEGF) is expressed in bone marrow blast cells, and an autocrine VEGF signaling mechanism has been established in MDS. Increased bone marrow angiogenesis and VEGF concentrations are adverse prognostic features in all of these patients. In this study, 69 patients were treated in two groups: hypomethylating agents or supportive care with oxymetholone±pyridoxine. We evaluated the MVD and VEGF expression of paraffin-embedded bone marrow samples from patients. We also investigated the relationship between angiogenesis-related biomarkers including MVD, VEGF expression, and clinical factors. The patient median age was 65 years, and the median follow-up duration was 28 months. MVD assessment among subtypes of WHO MDS classification showed that the MVD of RCUD was significantly lower than in other types (p=0.02). However, there was no significant difference in VEGF expression according to the subtype of MDS. Although MVD and VEGF expression did not differ between risk groups based on the IPSS, the low risk group tended to have lower expression of angiogenesis-related biomarkers. MDS patients receiving hypomethylating agents had significantly lower MVD expression in responders than in non-responders (6.13±3.38 vs. 9.89±2.10, respectively, p=0.039). In a consecutive evaluation at the time of diagnosis and 3 months after the initial treatment, the group with a decrease or no change of MVD had a higher response rate compared to that in the group with an increase of MVD (92.9% vs. 58.8%, respectively, p=0.045). Adverse prognostic factors included older age, MDS type other than RCUD, a higher IPSS risk group, and abnormal cytogenetics. Although angiogenesis-related markers did not demonstrate any significant prognostic association with survival, MVD (≥10n/mm ) and a strong expression of VEGF seemed to be associated with lower survival rate. These data suggested that the MVD value might be helpful in predicting responsiveness to treatment, especially in MDS patients treated with hypomethylating agents. Although angiogenesis-related markers including VEGF did not demonstrate a significant association with survival outcomes, we observed that high MVD and strong VEGF expression seemed to be associated with lower survival rate. Therefore, biologic markers related to angiogenesis might have a potential as prognostic factors for MDS patients.
[Mh] Termos MeSH primário: Imunossupressores/uso terapêutico
Síndromes Mielodisplásicas/classificação
Síndromes Mielodisplásicas/diagnóstico
Neovascularização Patológica/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores
Exame de Medula Óssea
Seres Humanos
Microvasos/diagnóstico por imagem
Meia-Idade
Síndromes Mielodisplásicas/tratamento farmacológico
Síndromes Mielodisplásicas/mortalidade
Neovascularização Patológica/diagnóstico por imagem
Oximetolona/uso terapêutico
Prognóstico
Piridoxina/uso terapêutico
Estudos Retrospectivos
Taxa de Sobrevida
Fator A de Crescimento do Endotélio Vascular/análise
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Immunosuppressive Agents); 0 (Vascular Endothelial Growth Factor A); KV2JZ1BI6Z (Pyridoxine); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160919
[St] Status:MEDLINE


  2 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27178489
[Au] Autor:Nejati V; Zahmatkesh E; Babaei M
[Ad] Endereço:Department of Histology and Embryology, Faculty of Science, Urmia University, Urmia, Iran.
[Ti] Título:Protective Effects of Royal Jelly on Oxymetholone-Induced Liver Injury in Mice.
[So] Source:Iran Biomed J;20(4):229-34, 2016 Sep.
[Is] ISSN:2008-823X
[Cp] País de publicação:Iran
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The present study was carried out to investigate the possible protective effects of royal jelly (RJ) on oxymetholone (OXM)-induced oxidative liver injuries in mice. METHODS: In total, 32 adult male NMRI mice were divided into four groups of eight mice each. Mice in groups 1 and 2 were orally administered 5 mg/kg/day OXM for 30 days. At the same time, mice in group 3 received RJ at a dose of 100 mg/kg/day. Saline control and RJ control groups were also included in this study. RESULTS: Administration of 5 mg/kg OXM resulted in a significant decrease in total antioxidant capacity and catalase activity, as well as a significant increase in malondialdehyde (P<0.05). In addition, OXM-administrated mice showed a slight increase in liver enzymes, including alanine amino transferase, aspartate amino transferase, and alkaline phosphatase. Although OXM caused histopathological changes in the liver, RJ could significantly improve all of the above-mentioned parameters at a dose of 100 mg/kg. CONCLUSION: The results of the present study indicated that RJ has a partially protective effect on OXM-induced liver toxicity in mice.
[Mh] Termos MeSH primário: Antioxidantes/farmacologia
Ácidos Graxos/farmacologia
Fígado/efeitos dos fármacos
Fígado/lesões
Estresse Oxidativo/efeitos dos fármacos
[Mh] Termos MeSH secundário: Alanina Transaminase/metabolismo
Fosfatase Alcalina/metabolismo
Animais
Aspartato Aminotransferases/metabolismo
Catalase/metabolismo
Masculino
Malondialdeído/metabolismo
Camundongos
Oximetolona/toxicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Fatty Acids); 4Y8F71G49Q (Malondialdehyde); EC 1.11.1.6 (Catalase); EC 2.6.1.1 (Aspartate Aminotransferases); EC 2.6.1.2 (Alanine Transaminase); EC 3.1.3.1 (Alkaline Phosphatase); L497I37F0C (royal jelly); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170407
[Lr] Data última revisão:
170407
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160515
[St] Status:MEDLINE


  3 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26653249
[Au] Autor:Tikka T; Mistry N; Janjua A
[Ad] Endereço:Department of ENT,Birmingham Heartlands (Teaching) Hospital,UK.
[Ti] Título:Acute unilateral sensorineural hearing loss associated with anabolic steroids and polycythaemia: case report.
[So] Source:J Laryngol Otol;130(3):309-13, 2016 Mar.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Unilateral sudden sensorineural hearing loss due to an infarct in the vertebrobasilar system has been widely reported. Most patients have a background of traditional coronary risk factors related to these cerebrovascular episodes. CASE REPORT: A 32-year-old male, a regular user of anabolic steroids, presented to the emergency department with unilateral sensorineural hearing loss and symptoms suggestive of an infarct of the anterior inferior cerebellar artery but in the absence of risk factors for ischaemic stroke. RESULTS: Magnetic resonance imaging confirmed the presence of infarction in the region supplied by the anterior inferior cerebellar artery. Polycythaemia was found on haematological analysis, which we believe was secondary to the use of anabolic steroids. The patient was commenced on aspirin as per the stroke management protocol. There was resolution of neurological symptomatology six weeks after the episode, but no improvement in hearing. CONCLUSION: To our knowledge, this is the first case report of unilateral sensorineural hearing loss secondary to the use of anabolic steroids causing polycythaemia. This cause should be considered in the differential diagnosis of patients presenting with sensorineural hearing loss, especially in young males, when no other risk factors can be identified.
[Mh] Termos MeSH primário: Anabolizantes/efeitos adversos
Androgênios/efeitos adversos
Perda Auditiva Neurossensorial/induzido quimicamente
Policitemia/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Audiometria de Tons Puros
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Oximetolona/efeitos adversos
Testosterona/efeitos adversos
Testosterona/análogos & derivados
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Androgens); 3XMK78S47O (Testosterone); 7Z6522T8N9 (testosterone enanthate); 855-19-6 (turinabol); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160216
[Lr] Data última revisão:
160216
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:151215
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215115003187


  4 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25955031
[Au] Autor:Kim JW; Ku SK; Han MH; Kim KY; Kim SG; Kim GY; Hwang HJ; Kim BW; Kim CM; Choi YH
[Ad] Endereço:Research Institute, Bio-Port Korea INC, Marine Bio-industry Development Center, Busan 619-912, Republic of Korea.
[Ti] Título:The administration of Fructus Schisandrae attenuates dexamethasone-induced muscle atrophy in mice.
[So] Source:Int J Mol Med;36(1):29-42, 2015 Jul.
[Is] ISSN:1791-244X
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:In the present study, we aimed to determine whether ethanol extracts of Fructus Schisandrae (FS), the dried fruit of Schizandra chinensis Baillon, mitigates the development of dexamethasone-induced muscle atrophy. Adult SPF/VAT outbred CrljOri:CD1 (ICR) mice were either treated with dexamethasone to induce muscle atrophy. Some mice were treated with various concentrations of FS or oxymetholone, a 17α-alkylated anabolic-androgenic steroid. Muscle thickness and weight, calf muscle strength, and serum creatine and creatine kinase (CK) levels were then measured. The administration of FS attenuated the decrease in calf thickness, gastrocnemius muscle thickness, muscle strength and weight, fiber diameter and serum lactate dehydrogenase levels in the gastrocnemius muscle bundles which was induced by dexamethasone in a dose-dependent manner. Treatment with FS also prevented the dexamethasone-induced increase in serum creatine and creatine kinase levels, histopathological muscle fiber microvacuolation and fibrosis, and the immunoreactivity of muscle fibers for nitrotyrosine, 4-hydroxynonenal, inducible nitric oxide synthase and myostatin. In addition, the destruction of the gastrocnemius antioxidant defense system was also inhibited by the administration of FS in a dose-dependent manner. FS downregulated the mRNA expression of atrogin-1 and muscle ring-finger protein-1 (involved in muscle protein degradation), myostatin (a potent negative regulator of muscle growth) and sirtuin 1 (a representative inhibitor of muscle regeneration), but upregulated the mRNA expression of phosphatidylinositol 3-kinase, Akt1, adenosine A1 receptor and transient receptor potential cation channel subfamily V member 4, involved in muscle growth and the activation of protein synthesis. The overall effects of treatment with 500 mg/kg FS were comparable to those observed following treatment with 50 mg/kg oxymetholone. The results from the present study support the hypothesis that FS has a favorable ameliorating effect on muscle atrophy induced by dexamethasone, by exerting anti-inflammatory and antioxidant effects on muscle fibers, which may be due to an increase in protein synthesis and a decrease in protein degradation.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/uso terapêutico
Força Muscular/efeitos dos fármacos
Músculo Esquelético/patologia
Atrofia Muscular/tratamento farmacológico
Schisandra/metabolismo
[Mh] Termos MeSH secundário: Aldeídos/imunologia
Animais
Anti-Inflamatórios/uso terapêutico
Antioxidantes/uso terapêutico
Creatina/sangue
Creatina Quinase/sangue
Dexametasona/farmacologia
Fibrose/tratamento farmacológico
Fibrose/prevenção & controle
L-Lactato Desidrogenase/sangue
Camundongos
Camundongos Endogâmicos ICR
Proteínas Musculares/genética
Tono Muscular/efeitos dos fármacos
Músculo Esquelético/efeitos dos fármacos
Atrofia Muscular/prevenção & controle
Miostatina/biossíntese
Miostatina/imunologia
Óxido Nítrico Sintase Tipo II/imunologia
Oximetolona/farmacologia
Fosfatidilinositol 3-Quinase/genética
Biossíntese de Proteínas/genética
Proteínas Proto-Oncogênicas c-akt/genética
RNA Mensageiro/biossíntese
Receptor A1 de Adenosina/genética
Proteínas Ligases SKP Culina F-Box/genética
Sirtuína 1/genética
Canais de Cátion TRPV/genética
Proteínas com Motivo Tripartido
Tirosina/análogos & derivados
Tirosina/imunologia
Ubiquitina-Proteína Ligases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aldehydes); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Drugs, Chinese Herbal); 0 (Muscle Proteins); 0 (Myostatin); 0 (RNA, Messenger); 0 (Receptor, Adenosine A1); 0 (TRPV Cation Channels); 0 (Tripartite Motif Proteins); 0 (Trpv4 protein, mouse); 3604-79-3 (3-nitrotyrosine); 42HK56048U (Tyrosine); 7S5I7G3JQL (Dexamethasone); EC 1.1.1.27 (L-Lactate Dehydrogenase); EC 1.14.13.39 (Nitric Oxide Synthase Type II); EC 2.3.2.27 (Fbxo32 protein, mouse); EC 2.3.2.27 (SKP Cullin F-Box Protein Ligases); EC 2.3.2.27 (Trim63 protein, mouse); EC 2.3.2.27 (Ubiquitin-Protein Ligases); EC 2.7.1.137 (Phosphatidylinositol 3-Kinase); EC 2.7.11.1 (Akt1 protein, mouse); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 2.7.3.2 (Creatine Kinase); EC 3.5.1.- (Sirt1 protein, mouse); EC 3.5.1.- (Sirtuin 1); K1CVM13F96 (4-hydroxy-2-nonenal); L76T0ZCA8K (Oxymetholone); MU72812GK0 (Creatine)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150509
[St] Status:MEDLINE
[do] DOI:10.3892/ijmm.2015.2200


  5 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25434823
[Au] Autor:Zhang QS; Benedetti E; Deater M; Schubert K; Major A; Pelz C; Impey S; Marquez-Loza L; Rathbun RK; Kato S; Bagby GC; Grompe M
[Ad] Endereço:Oregon Stem Cell Center, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: zhangqi@ohsu.edu.
[Ti] Título:Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling.
[So] Source:Stem Cell Reports;4(1):90-102, 2015 Jan 13.
[Is] ISSN:2213-6711
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Androgens are widely used for treating Fanconi anemia (FA) and other human bone marrow failure syndromes, but their mode of action remains incompletely understood. Aged Fancd2(-/-) mice were used to assess the therapeutic efficacy of oxymetholone (OXM) and its mechanism of action. Eighteen-month-old Fancd2(-/-) mice recapitulated key human FA phenotypes, including reduced bone marrow cellularity, red cell macrocytosis, and peripheral pancytopenia. As in humans, chronic OXM treatment significantly improved these hematological parameters and stimulated the proliferation of hematopoietic stem and progenitor cells. RNA-Seq analysis implicated downregulation of osteopontin as an important potential mechanism for the drug's action. Consistent with the increased stem cell proliferation, competitive repopulation assays demonstrated that chronic OXM therapy eventually resulted in stem cell exhaustion. These results expand our knowledge of the regulation of hematopoietic stem cell proliferation and have direct clinical implications for the treatment of bone marrow failure.
[Mh] Termos MeSH primário: Ciclo Celular/efeitos dos fármacos
Anemia de Fanconi/genética
Células-Tronco Hematopoéticas/efeitos dos fármacos
Células-Tronco Hematopoéticas/metabolismo
Osteopontina/genética
Oximetolona/farmacologia
Transcrição Genética/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Contagem de Células Sanguíneas
Medula Óssea/patologia
Ciclo Celular/genética
Proliferação Celular/efeitos dos fármacos
Modelos Animais de Doenças
Anemia de Fanconi/tratamento farmacológico
Anemia de Fanconi/patologia
Proteína do Grupo de Complementação D2 da Anemia de Fanconi/genética
Regulação da Expressão Gênica
Hematopoese/efeitos dos fármacos
Hematopoese/genética
Seres Humanos
Camundongos
Camundongos Knockout
Oximetolona/uso terapêutico
Pancitopenia/sangue
Pancitopenia/genética
Pancitopenia/patologia
Análise de Sequência de RNA
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Fanconi Anemia Complementation Group D2 Protein); 106441-73-0 (Osteopontin); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141202
[St] Status:MEDLINE


  6 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:25300168
[Au] Autor:Yang Q; Abudou M; Xie XS; Wu T
[Ad] Endereço:Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Woman's University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, Korea, South, 120-750.
[Ti] Título:Androgens for the anaemia of chronic kidney disease in adults.
[So] Source:Cochrane Database Syst Rev;(10):CD006881, 2014 Oct 09.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Anaemia occurs when blood contains fewer red blood cells and lower haemoglobin levels than normal, and is a common complication among adults with chronic kidney disease (CKD). Although a number of approaches are applied to correct anaemia in adults with CKD, the use of androgen therapy is controversial. OBJECTIVES: The aim of this review was to determine the benefits and harms of androgens for the treatment of anaemia in adult patients with CKD. SEARCH METHODS: We searched CENTRAL, the Cochrane Renal Group's Specialised Register, the Chinese Biomedicine Database (CBM), CNKI, VIP and reference lists of articles without language restriction. The most recent search was conducted in August 2014. SELECTION CRITERIA: All randomised controlled trials (RCTs) that assessed the use of androgens for treating anaemia of CKD in adults were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and assessed risk of bias in the included studies. Meta-analyses were performed using relative risk (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI). MAIN RESULTS: We included eight studies that reported data from 181 participants. Study quality was assessed as moderate in six studies, one was low quality, and one was high quality. The small number of included studies, and low participant numbers adversely influenced evidence quality overall.We found limited evidence (1 study, 24 participants) to indicate that oxymetholone can increase haemoglobin (Hb) (MD 1.90 g/dL, 95% CI 1.66 to 2.14), haematocrit (HCT) (MD 27.10%, 95% CI 26.49 to 27.71), change in albumin (MD 4.91 g/L, 95% CI 3.69 to 6.13), alanine aminotransferase (ALT) (MD 54.50 U/L, 95% CI 43.94 to 65.06), and aspartate aminotransferase (AST) (MD 47.33 U/L, 95% CI 37.69 to 56.97); and decrease high-density lipoprotein (HDL) (MD -15.66 mg/dL, 95% CI -24.84 to -6.48). We also found that compared with erythropoietin alone, nandrolone decanoate plus erythropoietin may increase HCT (3 studies, 73 participants: MD 2.54%, 95% Cl 0.96 to 4.12). Compared with erythropoietin (1 study, 27 participants), limited evidence was found to suggest that nandrolone decanoate can increase plasma total protein (MD 0.40 g/L, 95% CI 0.13 to 0.67), albumin (MD 0.20 g/L, 95% CI 0.01 to 0.39), and transferrin (MD 45.00 mg/dL, 95% CI 12.61 to 77.39) levels. Compared with no therapy (remnant kidney), evidence was found to suggest that nandrolone decanoate can increase Hb (2 studies, 33 participants: MD 1.04 g/dL, 95% Cl 0.66 to 1.41) and HCT (1 study, 24 participants: MD 3.70%, 95% Cl 0.68 to 6.72). Compared with no therapy (anephric), evidence was found (1 study, 5 participants) to suggest that nandrolone decanoate can increase Hb (MD 1.30 g/dL, 95% Cl 0.57 to 2.03), but nandrolone decanoate did not increase HCT (MD 2.00%, 95% Cl -0.85 to 4.85).However, oxymetholone was not found to reduce blood urea nitrogen (BUN), serum creatinine (SCr), cholesterol, or triglycerides; or increase plasma total protein, prealbumin, or transferrin. No evidence was found to indicate that nandrolone decanoate increased prealbumin or decreased BUN, SCr, AST, ALT, cholesterol, triglycerides, HDL or low-density lipoprotein (LDL). Adverse events associated with androgen therapy were reported infrequently. AUTHORS' CONCLUSIONS: We found insufficient evidence to confirm that use of androgens for adults with CKD-related anaemia is beneficial.
[Mh] Termos MeSH primário: Androgênios/uso terapêutico
Anemia/tratamento farmacológico
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Adulto
Anemia/sangue
Anemia/etiologia
Colesterol/sangue
Eritropoetina/uso terapêutico
Hematócrito
Seres Humanos
Nandrolona/análogos & derivados
Nandrolona/uso terapêutico
Oximetolona/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Androgens); 0 (Triglycerides); 11096-26-7 (Erythropoietin); 6PG9VR430D (Nandrolone); 97C5T2UQ7J (Cholesterol); H45187T098 (nandrolone decanoate); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:160602
[Lr] Data última revisão:
160602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141011
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD006881.pub2


  7 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25189728
[Au] Autor:Birgegård G
[Ad] Endereço:Department of Haematology, Uppsala University, Sweden. Electronic address: gunnar.birgegard@medsci.uu.se.
[Ti] Título:Does anything work for anaemia in myelofibrosis?
[So] Source:Best Pract Res Clin Haematol;27(2):175-85, 2014 Jun.
[Is] ISSN:1532-1924
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Anaemia is a common finding at diagnosis in myelofibrosis, and becomes a symptomatic problem in most patients with time. There are several treatment options for specific anaemia treatment, none of which has been tested in large, randomized, controlled trials. However, as myelofibrosis is not a disease with spontaneous remissions, even non-randomized trials carry weight. In this survey, the existing evidence will be analysed, both for the commonly used treatments like erythropoiesis-stimulating agents, androgens and thalidomide and for the new drugs in the area, and conclusions will be drawn concerning standard clinical anaemia treatment in myelofibrosis, which according to evidence from studies has a 40-50% chance of response in patients with not too advanced disease.
[Mh] Termos MeSH primário: Androgênios/uso terapêutico
Anemia/tratamento farmacológico
Hematínicos/uso terapêutico
Mielofibrose Primária/tratamento farmacológico
Talidomida/uso terapêutico
[Mh] Termos MeSH secundário: Anemia/complicações
Anemia/patologia
Transfusão de Sangue
Eritropoetina/uso terapêutico
Seres Humanos
Imunossupressores/uso terapêutico
Interferons/uso terapêutico
Oximetolona/uso terapêutico
Mielofibrose Primária/complicações
Mielofibrose Primária/patologia
Inibidores de Proteínas Quinases/uso terapêutico
Pirazóis/uso terapêutico
Talidomida/análogos & derivados
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Androgens); 0 (EPO protein, human); 0 (Hematinics); 0 (INCB018424); 0 (Immunosuppressive Agents); 0 (Protein Kinase Inhibitors); 0 (Pyrazoles); 11096-26-7 (Erythropoietin); 4Z8R6ORS6L (Thalidomide); 9008-11-1 (Interferons); D2UX06XLB5 (pomalidomide); F0P408N6V4 (lenalidomide); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:140905
[Lr] Data última revisão:
140905
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140906
[St] Status:MEDLINE


  8 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24557731
[Au] Autor:Ammatuna E; Nijziel MR
[Ad] Endereço:From the Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands and Department of Internal Medicine, Maxima Medical Centre, Eindhoven/Veldhoven, The Netherlands ammatuna@gmail.com.
[Ti] Título:Polycythemia and renal infarction in a bodybuilder.
[So] Source:QJM;107(8):661-2, 2014 Aug.
[Is] ISSN:1460-2393
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Infarto/induzido quimicamente
Rim/irrigação sanguínea
Policitemia/induzido quimicamente
Transtornos Relacionados ao Uso de Substâncias/complicações
[Mh] Termos MeSH secundário: Adulto
Anabolizantes/efeitos adversos
Seres Humanos
Infarto/diagnóstico por imagem
Rim/diagnóstico por imagem
Masculino
Oximetolona/efeitos adversos
Substâncias para Melhoria do Desempenho/efeitos adversos
Transtornos Relacionados ao Uso de Substâncias/diagnóstico
Tomografia Computadorizada por Raios X
Levantamento de Peso
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Performance-Enhancing Substances); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1505
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140222
[St] Status:MEDLINE
[do] DOI:10.1093/qjmed/hcu042


  9 / 374 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24054620
[Au] Autor:Madrakian T; Afkhami A; Rahimi M; Ahmadi M; Soleimani M
[Ad] Endereço:Faculty of Chemistry, Bu-Ali Sina University, Hamedan, Iran. Electronic address: madrakian@basu.ac.ir.
[Ti] Título:Preconcentration and spectrophotometric determination of oxymetholone in the presence of its main metabolite (mestanolone) using modified maghemite nanoparticles in urine sample.
[So] Source:Talanta;115:468-73, 2013 Oct 15.
[Is] ISSN:1873-3573
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A novel and sensitive extraction procedure using maghemite nanoparticles (γ-Fe2O3) modified with sodium dodecyl sulfate (SDS), as an efficient solid phase, was developed for removal, preconcentration and spectrophotometric determination of trace amounts of oxymetholone (OXM), in the presence of mestanolone (MSL). Combination of nanoparticle adsorption and easily magnetic separation was used for the extraction and desorption of OXM. The preparation of γ-Fe2O3 nanoparticles were obtained by co-precipitation method and their surfaces were modified by SDS. The size and properties of the produced γ-Fe2O3 nanoparticles were determined by X-ray diffraction analysis, FT-IR and scanning electron microscopy measurements. OXM and MSL became adsorbed at pH 3.0. The adsorbed drugs were then desorbed and determined spectrophotometrically using a selective complexation reaction for OXM. The calibration graph was linear in the range 15.0-3300.0 ng mL(-1) of OXM with a correlation coefficient of 0.9948. The detection limit of the method for determination of OXM was 4.0 ng mL(-1). The method was applied for the determination of OXM in human urine samples.
[Mh] Termos MeSH primário: Androgênios/urina
Di-Hidrotestosterona/análogos & derivados
Compostos Férricos/química
Nanopartículas de Magnetita/química
Oximetolona/urina
[Mh] Termos MeSH secundário: Androgênios/química
Calibragem
Di-Hidrotestosterona/química
Di-Hidrotestosterona/urina
Seres Humanos
Concentração de Íons de Hidrogênio
Limite de Detecção
Microscopia Eletrônica de Varredura
Oximetolona/química
Tamanho da Partícula
Espalhamento a Baixo Ângulo
Dodecilsulfato de Sódio/química
Extração em Fase Sólida/métodos
Espectrofotometria/métodos
Espectroscopia de Infravermelho com Transformada de Fourier
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Androgens); 0 (Ferric Compounds); 0 (Magnetite Nanoparticles); 08J2K08A3Y (Dihydrotestosterone); 1K09F3G675 (ferric oxide); 368GB5141J (Sodium Dodecyl Sulfate); L76T0ZCA8K (Oxymetholone); S712YZ168E (mestanolone)
[Em] Mês de entrada:1404
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130924
[St] Status:MEDLINE


  10 / 374 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23124786
[Au] Autor:Supasyndh O; Satirapoj B; Aramwit P; Viroonudomphol D; Chaiprasert A; Thanachatwej V; Vanichakarn S; Kopple JD
[Ad] Endereço:Division of Nephrology, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand. ouppatham@hotmail.com
[Ti] Título:Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients.
[So] Source:Clin J Am Soc Nephrol;8(2):271-9, 2013 Feb.
[Is] ISSN:1555-905X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVES: Sarcopenia is common in hemodialysis patients. This study examined whether the anabolic steroid oxymetholone improves muscle mass and handgrip strength in hemodialysis patients and possible mechanisms that might engender such changes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Forty-three eligible hemodialysis patients were randomly assigned to ingest oxymetholone or placebo for 24 weeks. Body composition, handgrip strength, and quality of life were measured during the study. Muscle biopsies were performed and analyzed for mRNA levels for myostatin, IGF-I, IGF binding proteins, and myosin heavy chains and protein expression. Muscle fiber types and diameter were assessed by reduced nicotinamide-adenine dinucleotide staining. RESULTS: There was a significantly greater increase in fat-free mass and handgrip strength and decrease in fat mass in the oxymetholone compared with the placebo group. Moreover, compared with baseline values, patients given oxymetholone exhibited an increase in fat-free mass, handgrip strength, physical functioning scores, and type I muscle fiber cross-sectional area and a decrease in fat mass, whereas patients receiving placebo did not undergo changes. There was a significantly greater increase in muscle mRNA levels for myosin heavy chain 2×, IGF-I, and IGF-II receptor with oxymetholone treatment than placebo. Liver enzyme rose significantly in the oxymetholone group, but the number of values greater than three times the upper limit of normal were not different between these groups. CONCLUSIONS: In hemodialysis patients, ingesting oxymetholone was associated with an increase in fat-free mass, handgrip strength, and muscle mRNA levels for several growth factors and a decrease in fat mass, but it also induced liver injury.
[Mh] Termos MeSH primário: Anabolizantes/administração & dosagem
Força Muscular/efeitos dos fármacos
Músculo Esquelético/efeitos dos fármacos
Músculo Esquelético/crescimento & desenvolvimento
Oximetolona/administração & dosagem
Diálise Renal
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anabolic Agents); L76T0ZCA8K (Oxymetholone)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:161025
[Lr] Data última revisão:
161025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121106
[St] Status:MEDLINE
[do] DOI:10.2215/CJN.00380112



página 1 de 38 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde